在开普敦进行的2026年艾滋病毒疫苗试验因特朗普返回后美国削减资金而停止, A 2026 HIV vaccine trial in Cape Town was halted by U.S. funding cuts linked to Trump’s return, then resumed after emergency aid.

2026年,在美国政府削减与特朗普总统重任相关资金,导致全球研究和医疗保健服务受阻后,开普敦的一项大型艾滋病毒疫苗试验被停止. In 2026, a major HIV vaccine trial in Cape Town was halted after U.S. funding cuts tied to former President Trump’s return to office disrupted global research and healthcare delivery. 由非洲科学家牵头的BRILIANT 011审判,在南非、盖茨基金会和韦尔肯信托会提供3 300万美元的紧急资金后恢复进行。 The BRILLIANT 011 trial, led by African scientists, resumed following $33 million in emergency funding from South Africa, the Gates Foundation, and the Wellcome Trust. 科学家们报告了重大的挫折,包括时间损失、供应链受损和培训中断。 Scientists reported significant setbacks, including lost time, damaged supply chains, and disrupted training. 在乌干达,削减援助造成挽救生命的抗逆转录病毒药物短缺,危及病人。 In Uganda, aid cuts caused shortages of life-saving antiretrovirals, endangering patients. 疫苗工作旨在针对各种艾滋病毒菌株生产广泛中和的抗体,但由于发展需求复杂和监管批准延迟,疫苗工作仍然进展缓慢,这突出表明全球卫生进步在政治不稳定情况下的脆弱性。 The vaccine effort, aimed at producing broadly neutralizing antibodies against diverse HIV strains, remains slow due to complex development needs and delayed regulatory approvals, underscoring the fragility of global health progress amid political instability.